Drug giant Sanofi becomes latest to cap US insulin prices

[Social Media]

Pharmaceutical giant Sanofi has capped the price of its insulin, becoming the last of three major manufacturers of the drug to curb soaring costs of the lifesaving medication in the US.

The French firm announced a $35 (£28) per month price cap on Lantus for those with private insurance. 

Sanofi's changes follow in the footsteps of other drugmakers, Eli Lilly and Novo Nordisk.

The move saves patients money, but it also may help the firm's bottom line.

The three companies make up 90% of the US insulin market and have faced public backlash and political pressure to reduce costs of the drug.

More than eight million Americans use insulin to control their diabetes, the American Diabetes Association says.

 

• The human cost of insulin in America